1. Home
  2. NEXA vs AGIO Comparison

NEXA vs AGIO Comparison

Compare NEXA & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nexa Resources S.A.

NEXA

Nexa Resources S.A.

HOLD

Current Price

$13.25

Market Cap

1.8B

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$33.62

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEXA
AGIO
Founded
1956
2007
Country
Luxembourg
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
2.0B
IPO Year
2017
2013

Fundamental Metrics

Financial Performance
Metric
NEXA
AGIO
Price
$13.25
$33.62
Analyst Decision
Hold
Buy
Analyst Count
5
8
Target Price
$10.40
$38.88
AVG Volume (30 Days)
770.8K
777.0K
Earning Date
05-06-2026
04-29-2026
Dividend Yield
0.93%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$43,011,000.00
Revenue This Year
$8.69
$76.75
Revenue Next Year
N/A
$170.73
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.82
$22.24
52 Week High
$16.89
$46.00

Technical Indicators

Market Signals
Indicator
NEXA
AGIO
Relative Strength Index (RSI) 44.43 48.19
Support Level $11.43 $32.54
Resistance Level $15.03 $36.04
Average True Range (ATR) 0.76 1.28
MACD -0.11 0.10
Stochastic Oscillator 4.21 42.77

Price Performance

Historical Comparison
NEXA
AGIO

About NEXA Nexa Resources S.A.

Nexa Resources SA operate large-scale, mechanized underground and open pit mines, as well as smelters. The company operates through two segments namely Mining and Smelting. Its Mining segment consists of various operating units includes mineral exploration activities and the production of zinc concentrates, copper concentrates and concentrates. The Smelting segment comprises operating units which include facilities recovering and refining zinc metal out of feed materials such as zinc concentrates or secondary feed materials. It generates maximum revenue from the Smelting segment. Geographically It has a presence in Brazil, Peru, the United States of America, Switzerland, Japan, Argentina, South Korea, Colombia, Vietnam, Malaysia and other countries.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Share on Social Networks: